Subsequent Events (Notes)

6 Months Ended

Jun. 30, 2013

Subsequent Events [Abstract]

Subsequent Event

Subsequent Event

On June 4, 2013, the Company entered into a share purchase agreement with ProFibrix and its equityholders to acquire all of the equity of ProFibrix, subject to the Company's satisfactory review of the then pending Phase 3 clinical trial results of ProFibrix's lead biologic, Fibrocaps. Following the Company's review of the Phase 3 trial results, on August 2, 2013, the Company notified ProFibrix that it wished to proceed to the closing of its acquisition of ProFibrix. The transaction closed on August 5, 2013 and, upon completion of the acquisition, ProFibrix became a wholly owned subsidiary of the Company (see note 13 “Acquisitions”).